These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9643625)

  • 21. Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients.
    Merry C; Barry MG; Mulcahy F; Tjia JF; Halifax KL; Heavey J; Kelly C; Back DJ
    AIDS; 1998 Feb; 12(3):325-7. PubMed ID: 9517997
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
    Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
    Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.
    Singh K; Dickinson L; Chaikan A; Back D; Fletcher C; Pozniak A; Moyle G; Nelson M; Gazzard B; Herath D; Boffito M
    Clin Pharmacol Ther; 2008 Jun; 83(6):867-72. PubMed ID: 17898705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.
    Falkensammer B; Fasser W; Scherer K; Zemann A; Parson W; Ulmer H; Dierich MP; Stoiber H
    Int J Immunopathol Pharmacol; 2005; 18(1):145-54. PubMed ID: 15698519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saquinavir. Clinical pharmacology and efficacy.
    Vella S; Floridia M
    Clin Pharmacokinet; 1998 Mar; 34(3):189-201. PubMed ID: 9533981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of garlic supplements on the pharmacokinetics of saquinavir.
    Piscitelli SC; Burstein AH; Welden N; Gallicano KD; Falloon J
    Clin Infect Dis; 2002 Jan; 34(2):234-8. PubMed ID: 11740713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy.
    Pawiński T; Pulik P; Gralak B; Horban A
    Acta Pol Pharm; 2008; 65(1):93-100. PubMed ID: 18536180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.
    Dickinson L; Back D; Pozniak A; Khoo S; Boffito M
    Ther Drug Monit; 2007 Jun; 29(3):361-7. PubMed ID: 17529895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection.
    Perry CM; Noble S
    Drugs; 1998 Mar; 55(3):461-86. PubMed ID: 9530549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
    Guidi M; Arab-Alameddine M; Rotger M; Aouri M; Telenti A; Decosterd LA; Buclin T; Csajka C;
    Chimia (Aarau); 2012; 66(5):291-5. PubMed ID: 22867538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
    Colombo S; Telenti A; Buclin T; Furrer H; Lee BL; Biollaz J; Decosterd LA;
    Ther Drug Monit; 2006 Jun; 28(3):332-8. PubMed ID: 16778716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The value of plasma antiretroviral drug monitoring in the management of HIV infected patients].
    Tréluyer JM
    Ann Med Interne (Paris); 2000 Jun; 151(4):291-6. PubMed ID: 10922957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.
    Kupferschmidt HH; Fattinger KE; Ha HR; Follath F; Krähenbühl S
    Br J Clin Pharmacol; 1998 Apr; 45(4):355-9. PubMed ID: 9578182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination study of Invirase and Norvir starting.
    AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361633
    [No Abstract]   [Full Text] [Related]  

  • 36. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
    Pereira SA; Branco T; Caixas U; Côrte-Real RM; Germano I; Lampreia F; Monteiro EC
    Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.
    Kim AE; Dintaman JM; Waddell DS; Silverman JA
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1439-45. PubMed ID: 9732409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
    Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
    Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.
    Khaliq Y; Gallicano K; Venance S; Kravcik S; Cameron DW
    Clin Pharmacol Ther; 2000 Dec; 68(6):637-46. PubMed ID: 11180024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.